7.85 % to Target, B. Riley FBR Keeps ‘Neutral’ Rating on Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Today

August 9, 2018 - By Jack Shaw

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Logo

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Rating Reaffirmed

The company has just set a price target of $18 on Arrowhead Pharmaceuticals (NASDAQ:ARWR) shares. This is 7.85 % from the close price. In analysts report sent to clients and investors on 8 August, B. Riley FBR reconfirmed their Neutral rating on shares of ARWR.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Ratings Coverage

Among 5 analysts covering Arrowhead Pharmaceuticals (NASDAQ:ARWR), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Arrowhead Pharmaceuticals has $18 highest and $400 lowest target. $10.40’s average target is -37.69% below currents $16.69 stock price. Arrowhead Pharmaceuticals had 11 analyst reports since February 12, 2018 according to SRatingsIntel. B. Riley & Co maintained Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) rating on Monday, February 12. B. Riley & Co has “Neutral” rating and $4 target. The firm has “Hold” rating given on Monday, February 12 by FBR Capital. The firm has “Hold” rating by FBR Capital given on Tuesday, March 27. Cantor Fitzgerald maintained the shares of ARWR in report on Monday, February 12 with “Neutral” rating. The firm has “Neutral” rating by FBR Capital given on Wednesday, August 8. The firm earned “Buy” rating on Monday, June 18 by Cantor Fitzgerald. The stock of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) earned “Hold” rating by FBR Capital on Monday, March 12. Cantor Fitzgerald maintained Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) rating on Wednesday, May 30. Cantor Fitzgerald has “Buy” rating and $1300 target. The stock of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) earned “Overweight” rating by Cantor Fitzgerald on Wednesday, May 9.

The stock increased 3.53% or $0.57 during the last trading session, reaching $16.69. About 533,479 shares traded. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has risen 540.13% since August 9, 2017 and is uptrending. It has outperformed by 527.56% the S&P500.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company has market cap of $1.47 billion. The Company’s pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target. It currently has negative earnings. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc.

More news for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) were recently published by: Benzinga.com, which released: “The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed’s Antibiotic Faces FDA Panel” on August 07, 2018. Fool.com‘s article titled: “Why Arrowhead Pharmaceuticals, Inc. Stock Slumped Today” and published on July 30, 2018 is yet another important article.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.